First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors

By sjmartinez • February 19, 2025

Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. ESMO Open. 2025 Feb 17;10(3):104291. doi: 10.1016/j.esmoop.2025.104291. Epub ahead of print. PMID: 39965362.

Tags: advanced or metastatic solid tumors, anti-drug antibodies, anti-PD-1–IL-15 fusion, antibody–cytokine fusion molecule, Hematology/Oncology, phase I study, Publications

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels

Sonni I, Gulpe A, Nickols NG, Schaffer D, Montagut L, Berenji GR, Rettig MB. Early detection and localization of recurrent prostate cancer using [Formula: see[...]

Lung Cancer Screening in California and Los Angeles County: A Landscape Analysis

Tupper HI, Gao YA, Cummings AL. Lung Cancer Screening in California and Los Angeles County: A Landscape Analysis. Cureus. 2026 Jun 27;18(6):e111619. doi: 10.7759/cureus.111619. PMID:[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]